Bessems J G, Vermeulen N P
Leiden/Amsterdam Center for Drug Research, Department of Pharmacochemistry, Vrije Universiteit, Amsterdam, The Netherlands.
Crit Rev Toxicol. 2001 Jan;31(1):55-138. doi: 10.1080/20014091111677.
An overview is presented on the molecular aspects of toxicity due to paracetamol (acetaminophen) and structural analogues. The emphasis is on four main topics, that is, bioactivation, detoxication, chemoprevention, and chemoprotection. In addition, some pharmacological and clinical aspects are discussed briefly. A general introduction is presented on the biokinetics, biotransformation, and structural modification of paracetamol. Phase II biotransformation in relation to marked species differences and interorgan transport of metabolites are described in detail, as are bioactivation by cytochrome P450 and peroxidases, two important phase I enzyme families. Hepatotoxicity is described in depth, as it is the most frequent clinical observation after paracetamol-intoxication. In this context, covalent protein binding and oxidative stress are two important initial (Stage I) events highlighted. In addition, the more recently reported nuclear effects are discussed as well as secondary events (Stage II) that spread over the whole liver and may be relevant targets for clinical treatment. The second most frequent clinical observation, renal toxicity, is described with respect to the involvement of prostaglandin synthase, N-deacetylase, cytochrome P450 and glutathione S-transferase. Lastly, mechanism-based developments of chemoprotective agents and progress in the development of structural analogues with an improved therapeutic index are outlined.
本文综述了对乙酰氨基酚(扑热息痛)及其结构类似物毒性的分子机制。重点关注四个主要主题,即生物活化、解毒、化学预防和化学保护。此外,还简要讨论了一些药理学和临床方面的内容。文章首先对扑热息痛的生物动力学、生物转化和结构修饰进行了概述。详细描述了与显著的物种差异以及代谢物器官间转运相关的Ⅱ相生物转化,以及细胞色素P450和过氧化物酶这两个重要的Ⅰ相酶家族的生物活化作用。深入阐述了肝毒性,因为这是扑热息痛中毒后最常见的临床观察结果。在此背景下,共价蛋白结合和氧化应激是突出的两个重要初始(Ⅰ期)事件。此外,还讨论了最近报道的核效应以及扩散至整个肝脏且可能是临床治疗相关靶点的继发事件(Ⅱ期)。对第二常见的临床观察结果——肾毒性,从前列腺素合酶、N - 脱乙酰酶、细胞色素P450和谷胱甘肽S - 转移酶的参与情况进行了描述。最后,概述了基于机制的化学保护剂的发展以及具有改善治疗指数的结构类似物的开发进展。